|
BLC USA
A company dedicated to developing early-stage projects through clinical trials pertaining to
Antimicrobial Resistance, working together with other partners to address the growing threat of AMR.Learn More
|
||
|
The US market for AMR gram-negative infections was estimated to be $12.7 billion in 2017. At that time, there were only 8 marketed antibiotics to treat these types of infections, with only 6 others known to be in development. |
||
|
Our world is quickly running out of treatment options. There is a critical need for new antibiotics; world organizations have come together to encourage and facilitate the discovery and development of new treatments. |
||
| “We are fast running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time.”
- Dr. Marie-Paule Kieny, W.H.O. Assistant Director General
|
.png)
.png)
